Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Rod who wrote (7373)	8/14/1998 10:10:00 AM
From: Rambi	Respond to of 8116

biz.yahoo.com Just found it.

To: Rod who wrote (7373)	8/24/1998 8:47:00 AM
From: Andriy Turhovach	Read Replies (1) \| Respond to of 8116

Here's the CEO news. The Bagman is gone: Cytogen Names Dr. H. Joseph Reiser President and Chief Executive Officer August 24, 1998 08:30 AM PRINCETON, N.J., Aug. 24 /PRNewswire/ -- CYTOGEN Corporation CYTO today announced that it has appointed H. Joseph Reiser, Ph.D. as president and chief executive officer and as a member of the board of directors. Dr. Reiser brings extensive pharmaceutical and marketing experience to CYTOGEN. Since 1981, he has held positions of increasing responsibility at Berlex Laboratories, the U.S. subsidiary of Schering AG, culminating in his promotion to corporate vice president and general manager, pharmaceuticals. During his 17-year tenure at Berlex, Dr. Reiser and his team achieved many milestones including the realization of significant revenue growth of the pharmaceutical division in his role as general manager from 1994 to 1998. Also during this time period, Dr. Reiser implemented new marketing programs including direct-to-consumer campaigns and was responsible for the initiation and management of diverse clinical development programs such as novel programs in pain management and gene therapy. In 1993, Berlex selected Dr. Reiser as its first vice president of technology and industry relations, where he identified and integrated strategic and functional technology priorities within the corporation. Prior to that time he was vice president of R&D responsible for preclinical research and development activities. His initial assignment at Berlex was to build a drug discovery effort via his appointment as director of pharmacology in 1981. Also during his time at Berlex, Dr. Reiser served as the first president of Schering Berlin's Venture Corporation from 1993 to 1994 where he secured funding participation in diverse areas of pharmaceutical R&D and joint ventures. In addition, Dr. Reiser was active in U.S.-based and international licensing activities. "We are delighted to have Joe join CYTOGEN as CEO," said Chairman James A. Grigsby. "His leadership and marketing-based experience in the pharmaceutical industry will be instrumental in the success of the company and its products. While we welcome his scientific knowledge and background, he was selected by the board because of his broad experience base in the pharmaceutical industry and associated marketing and business accomplishments." Dr. Reiser received his Ph.D. in physiology from Indiana University School of Medicine, where he also earned his Master and Bachelor of Science degrees. He has held various teaching positions and has been awarded fellowships at the Likoff Cardiovascular Institute, the American Heart Association (AHA) and the National Institutes of Health. He also has served on editorial boards, a Steering Committee of the Pharmaceutical Manufacturers Association and the board of several companies, including Berlex. He has authored more than 70 publications and presentations. The company also announced that John E. Bagalay Jr. will return to his prior obligations with Boston University after serving for the past seven months as CYTOGEN's interim chief executive officer. "I want to express on behalf of the CYTOGEN board our sincere appreciation to John Bagalay. John has moved the company forward by putting the strategic focus on our marketed products, and he was instrumental in concluding the recent Targon transaction. He has worked long and hard at this job and has seen the company through this difficult transition. We thank him and are pleased that he will continue as a member of the CYTOGEN board of directors," said Grigsby. CYTOGEN is a biopharmaceutical company engaged in the development, manufacture and commercialization of products for the targeted delivery of diagnostics and therapeutic substances directly to disease sites. CYTOGEN has demonstrated its ability to develop new technology from early discovery through clinical development, regulatory approval and commercial scale biologic manufacturing. Information in this press release which is not historical is forward looking and involves risks and uncertainties. Actual results may differ materially, for reasons discussed in the company's filings with the Securities and Exchange Commission, including commercial acceptance of the Company's products. SOURCE Cytogen Corporation

To: Rod who wrote (7373)	9/16/1998 12:52:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 8116

Cytogen's Cellcor Opers To Cease Sept. 18 Dow Jones Newswires PRINCETON, N.J. -- Cytogen Corp. (CYTO) plans to shut down its Cellcor unit operations Friday and reduce the workforce of its main operations as part of its continuing restructuring activities. In a press release Friday, Cytogen said it will report a charge in the third quarter for severance and other closure-related expenses. Cytogen said it will reduce its workforce by a total 30%, including staff cuts from the closure of Cellcor. The company said it decided to cease operations at Cellcor because it failed to achieve a management buyout agreement or sell the operations within an additional and final 45-day period the board had committed to complete the matter. Cytogen is a biopharmaceutical company that manufactures and commercializes products to diagnose and treat cancer and infectious diseases.